Company profile: T3D Therapeutics
1.1 - Company Overview
Company description
- Provider of remedial therapeutics for Alzheimer's disease and other CNS disorders, including T3D-959, an investigational oral drug candidate designed to treat Alzheimer's by improving brain glucose and lipid metabolism, potentially addressing multiple disease manifestations.
Products and services
- T3D-959: An investigational oral drug candidate for Alzheimer’s, architected to enhance brain glucose and lipid metabolism, potentially mitigating multiple disease manifestations through metabolic modulation.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to T3D Therapeutics
Torrey Pines Therapeutics
HQ: United States
Website
- Description: Provider of small molecule drug discovery and development in the United States, with a portfolio comprising candidates from proprietary drug-targeting platforms and in-licensed/acquired programs. As of August 31, 2010, the company's pipeline includes three clinical development programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Torrey Pines Therapeutics company profile →
Neurovance
HQ: United States
Website
- Description: Provider of clinical-stage neuroscience drug development, having discovered and developed centanafadine (CTN) to help adults and children with ADHD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurovance company profile →
Aderis Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical products for the diagnosis and treatment of cardio-renal and cardiovascular diseases, including adenosine agonists and antagonists; focused on discovery, development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aderis Pharmaceuticals company profile →
Neurocare
HQ: Germany
Website
- Description: Provider of a digital therapy platform integrating technology, training, software, and services to personalize mental health therapy after detailed assessment, plus devices for neuromodulation and monitoring, including TMS systems, neurofeedback (with optional biofeedback), EEG & QEEG systems, tDCS stimulators, and actigraphy devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurocare company profile →
Braeburn
HQ: United States
Website
- Description: Provider of opioid use disorder solutions, including BRIXADI, a weekly and monthly injectable medication for moderate to severe OUD, and an Investigator-Initiated Trials program that supports independent research to advance medical and scientific understanding of its products and related therapeutic areas.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Braeburn company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for T3D Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to T3D Therapeutics
2.2 - Growth funds investing in similar companies to T3D Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for T3D Therapeutics
4.2 - Public trading comparable groups for T3D Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →